Cigna earnings beat by $0.04, revenue topped estimates
Catheter Precision, Inc. (NYSE:VTAK), a Delaware-based medical instruments company, announced a new development this Monday. The company’s board of directors approved the issuance of a stock purchase warrant to Ladenburg Thalmann & Co., Inc. as partial compensation for its services in a recent financing deal.
The warrant allows Ladenburg Thalmann to acquire 257,143 shares of Catheter Precision’s common stock at a price of $0.5424 per share, significantly above the current trading price of $0.21. This move follows the company’s pipe financing, which concluded on May 12, 2025. The warrant will become exercisable pending approval from Catheter Precision’s stockholders, which the company aims to secure at its upcoming annual meeting on July 25, 2025. The warrant is set to expire on June 6, 2030.
The shares and the warrant have not been registered under the Securities Act of 1933. Catheter Precision has filed a preliminary proxy statement with the SEC, which includes information about the upcoming stockholder meeting and the warrant’s terms. According to InvestingPro analysis, while the company maintains more cash than debt on its balance sheet, it faces challenges with short-term obligations exceeding liquid assets. Subscribers to InvestingPro can access 12 additional key insights about VTAK’s financial health and growth prospects.
This development is part of Catheter Precision’s strategic financial maneuvers as it continues to navigate the medical instruments sector, with analysts forecasting 8.1% revenue growth for the current year. The company, formerly known as Ra Medical (TASE:BLWV) Systems, Inc., is headquartered in Fort Mill, South Carolina. This information is based on a press release statement filed with the Securities and Exchange Commission (SEC).
In other recent news, Catheter Precision, Inc. announced a significant change in its executive leadership. Earlier this week, the company disclosed that Marie-Claude Jacques, the Chief Commercial Officer, has departed from her role. In the interim, David Jenkins, who is the Executive Chairman of the Board and Chief Executive Officer, will temporarily take on the responsibilities of Chief Commercial Officer. This change was made public through a Form 8-K filing with the Securities and Exchange Commission (SEC), which is a standard procedure for publicly traded companies to inform shareholders of major events. The company, which operates in the surgical and medical instruments sector, is headquartered in Fort Mill, South Carolina. Known previously as Ra Medical Systems, Inc., Catheter Precision is not classified as an emerging growth company under SEC definitions. This leadership transition is part of the company’s ongoing efforts to enhance its executive team. The announcement was officially communicated through a press release statement filed with the SEC.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.